Hypercalcemia is the most common endocrine complication affecting patients with malignancies, and is of considerable clinical importance. This book describes the underlying mechanisms of hypercalcemia associated with cancer, and provides a review of diagrams and clinical management with special emphasis on therapeutic agents. This monograph provides a wealth of experience in basic bench research in this area as well as extensive clinical experience with a large number of patients.
Sunil J. Wimalawansa
Cisplatin amifostine (WR 2721) amylin calcitonin (CT) echistatin epidermal growth factor (EGF) fibroblast grothw factor (FGF) lymphotoxin myeloma tumor necrosis factor (TNF)